Advances in mRNA-Based Melanoma Vaccines: A Narrative Review of Lipid Nanoparticle and Dendritic Cell Delivery Platforms
Top Cited Papers
Open Access
Abstract
Melanoma remains one of the deadliest cutaneous malignancies worldwide, and despite advances in systemic therapy, recurrence and treatment resistance remain frequent challenges. Following the success of COVID-19 mRNA vaccines, mRNA-based cancer vaccines targeting melanoma antigens have emerged as a promising therapeutic direction. This review summarizes current evidence on mRNA melanoma vaccines, focusing on two leading delivery platforms: lipid nanoparticles (LNPs) and dendritic cell (DC) vaccines. A comprehensive search of MEDLINE, Embase, and Scopus from 2015 to 2025 identified clinical trials, preclinical studies, and review articles evaluating mRNA vaccine constructs and delivery strategies. Completed clinical studies demonstrate that personalized LNP-formulated mRNA vaccines can enhance neoantigen-specific T-cell responses and improve recurrence-free survival, particularly when combined with immune checkpoint inhibitors. DC-based mRNA vaccines also show potent immunogenicity, with stronger responses observed when DC maturation is optimized. Ongoing trials continue to investigate next-generation LNP formulations, DC priming strategies, and personalized neoantigen approaches. Overall, current evidence indicates that both LNP and DC platforms can augment antitumor immunity by broadening T-cell responses and enhancing checkpoint inhibition. Continued refinement of delivery vehicles, neoantigen selection, and scalable manufacturing processes will be essential to realizing the full clinical potential of mRNA vaccines in melanoma.Keywords
This publication has 84 references indexed in Scilit:
- Personalized precision: Revolutionizing cancer treatment with mRNA-based vaccines in melanoma therapy2025
- Engineering Lipid Nanoparticles for mRNA ImmunotherapyWIREs Nanomedicine and Nanobiotechnology, 2025
- A Universal Strategy of Anti‐Tumor mRNA Vaccine by Harnessing “Off‐the‐Shelf” ImmunityAdvanced Science, 2025
- DNA and mRNA vaccines: Significant therapeutic approach against cancer management2024
- Recent progress, challenges (stability and in vivo distribution), and opportunities of DNA & mRNA vaccine in cancer immunotherapy2024
- A biodegradable lipid nanoparticle delivers a Cas9 ribonucleoprotein for efficient and safe in situ genome editing in melanomaActa Biomaterialia, 2024
- Adverse events following COVID‐19 mRNA vaccines: A systematic review of cardiovascular complication, thrombosis, and thrombocytopeniaImmunity, Inflammation and Disease, 2023
- Comparison of Clinicopathologic Features and Survival of Histopathologically Amelanotic and Pigmented MelanomasJAMA Dermatology, 2014
- The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: A systematic reviewInternational Journal of Cancer, 2006
- Clinicopathological Features of and Risk Factors for Multiple Primary MelanomasJAMA, 2005